Hospital Infanta Leonor-ko ikertzaileekin lankidetzan egindako argitalpenak (8)

2022

  1. Azacitidine vs. Decitabine in Unfit Newly Diagnosed Acute Myeloid Leukemia Patients: Results from the PETHEMA Registry

    Cancers, Vol. 14, Núm. 9

  2. Use of Venetoclax in Patients with Relapsed or Refractory Acute Myeloid Leukemia: The PETHEMA Registry Experience

    Cancers, Vol. 14, Núm. 7

2021

  1. A phase 3 trial of azacitidine versus a semi-intensive fludarabine and cytarabine schedule in older patients with untreated acute myeloid leukemia

    Cancer, Vol. 127, Núm. 12, pp. 2003-2014

  2. Characteristics, clinical outcomes, and risk factors of SARS-COV-2 infection in adult acute myeloid leukemia patients: experience of the PETHEMA group

    Leukemia and Lymphoma, Vol. 62, Núm. 12, pp. 2928-2938

2019

  1. Differences in ex-vivo Chemosensitivity to Anthracyclines in First Line Acute Myeloid Leukemia

    Mediterranean Journal of Hematology and Infectious Diseases, Vol. 11

2018

  1. Real life experience with frontline azacitidine in a large series of older adults with acute myeloid leukemia stratified by MRC/LRF score: results from the expanded international E-ALMA series (E-ALMA+)

    Leukemia and Lymphoma, Vol. 59, Núm. 5, pp. 1113-1120

2017

  1. Characteristics and management of primary and other immune thrombocytopenias: Spanish registry study

    Hematology, Vol. 22, Núm. 8, pp. 484-492

2014

  1. Pharmacological profiles of acute myeloid leukemia treatments in patient samples by automated flow cytometry: A bridge to individualized medicine

    Clinical Lymphoma, Myeloma and Leukemia, Vol. 14, Núm. 4, pp. 305-318